Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy

MONTREAL, Oct. 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has decided to reschedule its webcast and conference call to discuss financial results for the 2012 third quarter, which was previously scheduled for Wednesday, October 31, 2012 at 8 a.m. ET, due to the severe weather conditions and power outages associated with Hurricane Sandy. The webcast and conference call has been rescheduled for November 2, 2012 at 8 a.m. ET and the financial results will be issued at 6:00 a.m. ET.

The dial-in number to participate on this call is (877) 281-0402, confirmation code 39252322.  International callers should dial (631) 813-4869, confirmation code 39252322. A replay will be available approximately two hours following the conclusion of the conference call to Friday, November 9, 2012, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 39252322.

The webcast and slide presentation will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.

RELATED LINKS
http://www.valeant.com